Clinical trial
Effectiveness and Safety of Once Weekly Insulin Icodec Used With DoseGuide Versus Once Daily Basal Insulin Analogues in an Insulin naïve Type 2 Diabetes Population in a Clinical Practice Setting
NCT04760626 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effectiveness and Safety of Once Weekly Insulin Icodec Used With DoseGuide Versus Once Daily Basal Insulin Analogues in an Insulin naïve Type 2 Diabetes Population in a Clinical Practice Setting
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 1, 2021
- Completion date
- August 29, 2022
- Enrollment
- 1,085 (actual)
- Sites
- 311
Conditions
As the registry lists them; a condition with its own page is linked.